| Literature DB >> 19243818 |
Martha Q Lacy1, Susanna Jacobus, Emily A Blood, Neil E Kay, S Vincent Rajkumar, Philip R Greipp.
Abstract
The Eastern Cooperative Oncology Group (ECOG) conducted a phase II trial of interleukin-12 (IL-12) for plateau phase multiple myeloma. Patients were initially treated with IL-12 250 ng/kg I.V. daily for 5 days every 3 weeks. The trial was modified due to toxicity after the first 16 patients. IL-12 was given 300 ng/kg subcutaneously twice weekly for 24 weeks. Of 48 eligible patients, there were 4 objective responses (8.3%), all CR. The median survival and progression-free survival were 42.8 and 11.4 months. Unacceptable grade 3 or 4 non-hematologic toxicity (31% with IL-12 subcutaneously and 63% with IL-12 intravenously) was observed.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19243818 PMCID： PMC4070590 DOI： 10.1016/j.leukres.2009.01.020
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156